Thank you for Subscribing to Life Science Review Weekly Brief
Eledon plans to start the experiment in the fourth quarter of this year, with interim data read-outs starting late in 2022
FREMONT, CA: “At CareDx, we focus on innovation and working with leaders in the transplant space. With Eledon, we continue this proven strategy by partnering on their AT-1501 development program,” states Reg Seeto, CEO and President of CareDx. CareDx, a leading precision medicine company centered on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, and Eledon Pharmaceuticals, a clinical-stage biopharmaceutical business developing precision therapies that target the CD40 Ligand pathway for use in organ and cellular transplantation, and for the diagnosis of amyotrophic lateral sclerosis (ALS) and autoimmune diseases, come together for a collaborative research agreement to use AlloSure to help assess the efficacy of Eledon’s investigational AT-1501 in the prevention of rejection in approaching renal transplantation trials.
“This agreement allows us to bring our leading innovative offerings like AlloSure earlier in drug development as Eledon develops the next generation of transplant therapeutics,” added Seeto.
Eledon disclosed in July that it has gained Health Canada approval to begin human trials of AT-1501 in kidney transplantation. The AT-1501 safety, effectiveness, and pharmacokinetics in de novo kidney transplant patients will be evaluated in a multicenter, open-label experiment with 6 to 12 subjects. Eledon plans to start the experiment in the fourth quarter of this year, with interim data read-outs starting late in 2022.
“This collaboration agreement provides Eledon with access to CareDxs best-in-class technologies,” stated David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “Our partners experience with biomarkers and predictive algorithms gives us the opportunity to gather important insights on the potential for longer term allograft survival rates as we advance AT-1501 through clinical development. We are pleased to partner with the market leader in broader transplantation services and look forward to working together towards supporting transplant patients.”